AJP - Lung Add DOIs to your references at manuscript stage!
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Lung Cell Mol Physiol 295: L988-L997, 2008. First published September 19, 2008; doi:10.1152/ajplung.90202.2008
1040-0605/08 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
295/6/L988    most recent
90202.2008v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wu, Y.
Right arrow Articles by Gunst, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wu, Y.
Right arrow Articles by Gunst, S. J.

Integrin-linked kinase regulates smooth muscle differentiation marker gene expression in airway tissue

Yidi Wu, Youliang Huang, B. Paul Herring, and Susan J. Gunst

Department of Cellular and Integrative Physiology, Indiana University School of Medicine, Indianapolis, Indiana

Submitted 22 February 2008 ; accepted in final form 17 September 2008


   ABSTRACT
TOP
 ABSTRACT
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Phenotypic changes in airway smooth muscle occur with airway inflammation and asthma. These changes may be induced by alterations in the extracellular matrix that initiate signaling pathways mediated by integrin receptors. We hypothesized that integrin-linked kinase (ILK), a multidomain protein kinase that binds to the cytoplasmic tail of β-integrins, may be an important mediator of signaling pathways that regulate the growth and differentiation state of airway smooth muscle. We disrupted signaling pathways mediated by ILK in intact differentiated tracheal muscle tissues by depleting ILK protein using ILK antisense. The depletion of ILK protein increased the expression of the smooth muscle differentiation marker genes myosin heavy chain (SmMHC), SM22{alpha}, and calponin and increased the expression of SmMHC protein. Conversely, the overexpression of ILK protein reduced the mRNA levels of SmMHC, SM22{alpha}, and calponin and SmMHC protein. Analysis by chromatin immunoprecipitation showed that the binding of the transcriptional regulator serum response factor (SRF) to the promoters of SmMHC, SM22{alpha}, and calponin genes was increased in ILK-depleted tissues and decreased in tissues overexpressing ILK. ILK depletion also increased the amount of SRF that localized within the nucleus. ILK depletion and overexpression, respectively, decreased and increased the activation of its downstream substrate protein kinase B (PKB/Akt). The pharmacological inhibition of Akt activity also increased SRF binding to the promoters of smooth muscle-specific genes and increased expression of smooth muscle proteins, suggesting that ILK may exert its effects by regulating the activity of Akt. We conclude that ILK is a critical regulator of airway smooth muscle differentiation. ILK may mediate signals from integrin receptors that control airway smooth muscle differentiation in response to alterations in the extracellular matrix.

smooth muscle myosin heavy chain; serum response factor

SMOOTH MUSCLE CELLS ARE highly plastic in cell culture and have the ability to modulate their phenotype between a contractile and a proliferative synthetic state (5, 14, 15, 28). The phenotypic modulation of smooth muscle cells is characterized by changes in the expression of genes encoding smooth muscle-specific proteins, including smooth muscle myosin heavy chain (SmMHC), SM22{alpha}, {alpha}- and {gamma}-actin, and calponin-h1, which are required for the contractile function of smooth muscle tissues (14, 28). Phenotypic changes in airway smooth muscle may be induced by pathophysiological conditions such as airway inflammation and asthma, and these changes may contribute to airway smooth muscle dysfunction (15, 34).

Chronic asthma is often characterized by structural remodeling of the airway wall and abnormalities in the extracellular matrix, which may induce changes in the airway smooth muscle phenotype (19, 32). The phenotypic properties of smooth muscle cells are sensitive to alterations in their extracellular environment (4). In cultured airway smooth muscle cells, changes in the composition of the extracellular matrix can modulate the expression of contractile marker proteins as well as their proliferative index (18, 19).

The principal receptors for extracellular matrix proteins are transmembrane heterodimeric integrin proteins, which are composed of {alpha}- and β-subunits. Integrin receptors have been implicated in the regulation of both smooth and skeletal muscle differentiation (4, 9, 22, 30, 36). However, the signaling pathways by which signals sensed by integrin receptors are transduced to regulate gene transcription and smooth muscle cell phenotype remain to be elucidated.

Integrin-linked kinase (ILK) is an integrin β1-cytoplasmic domain-binding protein that mediates structural connections between integrin proteins and the actin cytoskeleton through several of its binding partners (3, 10, 16, 26, 40). ILK is positioned to transduce integrin-mediated signals from the extracellular matrix to a variety of intracellular signaling cascades that regulate cytoskeletal organization and gene expression (3, 7, 16, 35, 38).

ILK associates with integrin receptors and regulates the organization of macromolecular complexes at the extracellular matrix/cytoskeletal junctions (26, 38, 40, 41). We previously demonstrated that ILK plays a critical role in the organization and localization of these macromolecular complexes to the integrin-associated adhesion sites during the contractile activation of airway smooth muscle and that these macromolecular adhesion complexes are critical for the regulation of cytoskeletal organization and contractility of airway smooth muscle tissues (38). However, a role for ILK in the regulation of smooth muscle differentiation has not been described. We hypothesized that ILK may also mediate signals to the nucleus that regulate airway smooth muscle phenotype and differentiation.

We evaluated the role of ILK in the regulation of airway smooth muscle phenotype by depleting or overexpressing ILK protein in airway smooth muscle tissues and then determining the subsequent effects on expression of smooth muscle differentiation marker genes and their transcriptional regulators. Because the extracellular matrix environment and cell morphology play a critical role in determining the effects of integrin-mediated signaling pathways, intact fully differentiated tracheal smooth muscle tissues were used for these studies. Our results demonstrate that ILK plays a critical role in regulating the expression of smooth muscle differentiation marker genes in intact airway smooth muscle tissues.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Preparation of smooth muscle tissues. All experimental procedures were reviewed and approved by the Institutional Animal Care and Use Committee, Indiana University School of Medicine. Mongrel dogs were euthanized according to proscribed procedures, and the trachea was immediately removed and immersed in physiological saline solution (PSS) at 22°C (composition in mM: 110 NaCl, 3.4 KCl, 2.4 CaCl2, 0.8 MgSO4, 25.8 NaHCO3, 1.2 KH2PO4, and 5.6 glucose). The solution was aerated with 95% O2-5% CO2 to maintain a pH of 7.4. Rectangular strips of tracheal muscle 1 mm in diameter and 10 mm in length were dissected after removal of the epithelium and connective tissue layer. Each muscle strip was placed in PSS at 37°C in a 25-ml organ bath and attached to a Grass force transducer for the measurement of force. At the beginning of each experiment, muscle length was progressively increased until the force of active contraction in response to a contractile stimulus reached a maximum (optimal length).

The depletion or overexpression of ILK protein in the muscle tissues was induced by introducing oligodeoxynucleotides (ODNs) dissolved in Tris-EDTA buffer or plasmids encoding human ILK cDNA in muscle strips according to experimental procedures described below. Muscle tissues were then mounted on metal hooks at the optimal length and incubated for 1 or 2 days in DMEM with ODNs or plasmids in the medium. Tissues were then quickly frozen using liquid N2-cooled tongs and pulverized under liquid N2 using a mortar and pestle for biochemical analysis, or they were enzymatically dissociated for fluorescence imaging.

Reagents and antibodies. Antisense ODNs to ILK with the following sequence were designed to suppress ILK protein expression in canine tracheal smooth muscle tissues: 5'-TCCCGTGGTAGCA GTCG-3'. ILK sense ODNs (5'-CGACTGCTACCACGGGAG-3') were also used to test for possible nonspecific effects of the ODNs on tracheal muscle tissues. All ODNs were phosphorothiolated to enhance their intracellular stability. According to sequence-matching results obtained from The National Center for Biotechnology Information, these sequences are not homologous to sequences of any other contractile or cytoskeletal proteins.

Plasmids encoding full-length human ILK cDNA with a FLAG epitope at the amino terminus were cloned into the EcoRI/XbaI sites of the pFLAG-CMV-2 vector. Plasmids were kindly provided by Dr. Chuanyue Wu (Department of Pathology, University of Pittsburgh).

Antibodies used in these experiments were as follows: mouse monoclonal anti-human ILK and rabbit polyclonal anti-ILK (Upstate Biotechnology); monoclonal anti-human smooth muscle myosin (clone HSM-V), monoclonal anti-human calponin (clone hCP), monoclonal anti-{alpha}-actinin (clone EA-53), anti-FLAG (clone M2) (Sigma-Aldrich); polyclonal anti-human SM22{alpha} (custom made by Proteintech Group, Chicago, IL); rabbit polyclonal serum response factor (SRF; clone G-20; Santa Cruz Biotechnology); protein kinase B (Akt) anti-phospho Ser473 and anti-Akt (Abcam); and goat anti-rabbit conjugated to Alexa 488 (Molecular Probes). Propidium iodide (PI) was obtained from Sigma-Aldrich. Akt Inhibitor VIII (Isozyme-Slective, Akt-1/2) was purchased from Calbiochem.

Introduction of ODNs or plasmids in tracheal smooth muscle tissues. ILK antisense or sense ODNs or plasmids encoding full-length ILK were introduced in the smooth muscle tissues by the method of reversible permeabilization (31, 39). Muscle tissues attached to a metal hooks were placed in 0.5-ml tubes and incubated successively in each of the following solutions (amounts in mM): solution 1 (at 4°C for 120 min): 10 EGTA, 5 Na2ATP, 120 KCl, 2 MgCl2, and 20 N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid (TES); solution 2 (at 4°C overnight): 0.1 EGTA, 5 Na2ATP, 120 KCl, 2 MgCl2, and 20 TES; 10 µM antisense or sense ODNs or 10 µg/ml plasmids; solution 3 (at 4°C for 30 min): 0.1 EGTA, 5 Na2ATP, 120 KCl, 10 MgCl2, and 20 TES; and solution 4 (at 22°C for 60 min), containing 110 NaCl, 3.4 KCl, 0.8 MgSO4, 25.8 NaHCO3, and 1.2 KH2PO4 and aerated with 95% O2-5% CO2. After 30 min in solution 4, CaCl2 was added gradually to reach a final concentration of 2.4 mM. The tissues strips treated with ILK antisense or sense ODNs were then incubated for 1 day in DMEM containing 5 mM Na2ATP, 100 U/ml penicillin, 100 µg/ml streptomycin, and 10 µM oligonucleotides at 37°C and 5% CO2. Plasmid-treated tissues were incubated for 2 days in the same medium with 10 µg plasmids. Sham-treated tissues were studied in parallel in all protocols and were subjected to identical protocols except that plasmids and antisense were omitted from the solutions during the reversible permeabilization procedures.

Quantitation of mRNA. Total RNA was isolated from the pulverized muscle extracts using the RNeasy Mini Kit (Qiagen, Chatsworth, CA) according to the manufacturer's instructions. The eluted RNA was quantified using the Quant-iT RNA Assay Kit (Invitrogen). Total RNA from each muscle (2.5 µg) was converted to cDNA using SuperScript III reverse transcriptase (Invitrogen) with oligo(dT) as primer. The canine gene-specific primers were as follows: SmMHC (5'-GAAGCCTCCGTGCTACACAAC-3' and 5'-GCAGAAGAGGCCAGAGTACGTATAT-3'), SM22{alpha} primers (5'-GAAGGCGGCTGAGGA CTCT-3' and 5'-CAACAGTCTGGAACATGTCAGTCTT-3'), calponin (5'-GCCAGGCTCCGTGAAGAA-3' and 5'-TTGGTGATGGCCTTGATGAA-3'), and {alpha}-actinin (5'-CCTCGGCTTCTGTGCTTTG-3' and 5'-TAGTCAATCAGCTCGGGCC-3') and were designed using Primer Express 2.0 (Applied Biosystems). Blast was conducted to confirm that primer pairs only matched the sequence of the target genes.

Quantitative real-time PCR was performed using an Applied Biosystems 7500 Real Time PCR System with SYBR Green PCR Master Mix. The changes in mRNA levels for target genes were quantified using relative quantitative analysis with 18S rRNA as internal reference. The relative mRNA [respiratory quotient (RQ)] was computed as 2Formula where {Delta}{Delta}Ct = (Ct sham – Ct 18S) – (Ct test – Ct 18S).

Protein extraction and analysis by immunoblot. After incubation with ODNs or plasmids, smooth muscle tissues were pulverized in liquid N2. Proteins were extracted and separated using 6–8% SDS-PAGE, with the exception of SM22{alpha}, which was separated on a 12% trycine gel. Proteins were then transferred to nitrocellulose membranes, and the membranes were immunoprobed for proteins of interest. Proteins were visualized by enhanced chemiluminescence and quantified by scanning densitometry.

Enzymatic digestion of smooth muscle tissues and fluorescent staining of dissociated cells. Smooth muscle cells were enzymatically dissociated from sham-treated and ILK antisense-treated tracheal muscle strips as previously described (27, 37). Muscle strips were placed in dissociation solution and then incubated in a shaking water bath at 37°C for 20–30 min. The tissue was then rinsed and triturated with a pipette to liberate individual smooth muscle cells from the tissue. The solution of dissociated cells was poured over glass cover slips, and the cells were allowed to adhere to the slides for 2 h at room temperature. Cells were then fixed and incubated with SRF antibody and secondary antibody conjugated to fluorescent green (Alexa 488). The cells were counterstained for nuclear DNA with the fluorescent indicator PI, which emits at 615 nm when bound to DNA.

Analysis of SRF localization in dissociated cells. The cellular localization of fluorescently labeled SRF was evaluated in the dissociated smooth muscle cells using a Zeiss LSM 510 laser scanning confocal microscope with an Apo x63 oil-immersion lens objective (1.4 numerical aperture). Alexa 488-labeled (green) proteins were excited with a 488-nm argon laser light, and fluorescence emissions were collected at 500–530 nm. PI was excited at 535 nm, and emissions were collected at 630 nm. The optical pinhole was set to resolve optical sections of 1 µm in cell thickness. The plane of focus was set midway between the bottom and the top of the cell. Fluorescence intensity measurements were standardized among all cells compared within a single experiment by maintaining the same microscope settings. Images of smooth muscle cells were analyzed for regional differences in fluorescence intensity of labeled SRF by quantifying the pixel intensity using a series of cross-sectional line scans through the area of the nucleus (3 lines) and the cytoplasm (4 lines) (see Fig. 3, A and B). The ratio of nuclear to cytoplasmic SRF was determined for each cell by calculating the average pixel intensity of the lines across the nucleus relative to the lines across the cytoplasm.

Cell fractionation and extraction of nuclear and cytoplasmic protein. Nuclear and cytoplasmic protein extracts were prepared from sham-treated and ILK antisense-treated smooth muscle tissues using a commercially available kit (Active Motif) as follows: 300 mg muscle tissue from sham-treated or ILK-AS treated tissues were diced and homogenized. Homogenized tissues were centrifuged and the supernatant reserved as the cytoplasmic fraction. The pellet was resuspended in lysis buffer, centrifuged, and the supernatant reserved as the nuclear fraction. Proteins from nuclear and cytoplasmic extracts were analyzed by immunoblot. Glyceraldehyde-3-phosphate dehydrogenase was used as marker for the cytosolic fraction.

Chromatin immunoprecipitation assay. The binding of SRF to the promoters of smooth muscle-specific genes was performed according to the protocols described in a commercially available kit (Upstate Biotech) as follows: tissues were chopped into small pieces and treated with 1% formaldehyde for 15 min at room temperature to cross-link protein and DNA. After the tissues were homogenized using 1% SDS lysis buffer, 600-µl lysate of each group was sonicated using a Sonic Dismembranator (Fisher Scientific) and immunoprecipitated using SRF antibody or with IgG alone as a negative control. The immune complexes were recovered using agarose beads. DNA that was isolated from immunoprecipitated chromatin fragments (SRF and IgG) was subjected to quantitative RT-PCR using primers flanking the CCArGG box [CC (A/T-rich) GG] elements from SmMHC, SM22{alpha}, and calponin promoters. Primers for the {alpha}-actinin promoter were used as a negative control. Aliquots of sheared DNA from the tissue lysates that had not been immunoprecipitated were also included in the RT-PCR reaction (input) to adjust for differences in the amount of DNA in different tissue samples. Primer sequences used were as follows: SmMHC sense primer, 5'-CTGCGCGGG ACCATATTTAGTCAGGGGGAG-3'; SmMHC antisense primer, 5'-CTGGGCGGGAGACAACCC AAAAAGGCCAGG- 3' (24); SM22{alpha} sense primer, 5'-GCTCCATCTCCAAAGCACGCAG-3'; SM22{alpha} antisense primer, 5'-GACTCCACACAGGCTCCATATTT-3'; calponin sense primer, 5'-GGGCCG GTTTGCTTTATAAA-3'; calponin antisense primer, 5'-CCCAGACAGGTTCCGAGACT-3'; {alpha}-actinin sense primer, 5'-TGTGGAGAGCGGCCCAGG-3'; and {alpha}-actinin antisense primer, 5'-CCTCGG TTCCCATGGCAG-3'. The amount of amplification of the target gene promoter for sample was quantitated from the difference in the cycle number (Ct) of the SRF immunoprecipitate DNA and the input DNA for that sample. The relative differences in the amount of SRF binding to the promoters of genes from ILK antisense-treated tissues and ILK wild-type-treated tissues, and for tissues treated or not treated with Akt inhibitor, were determined by calculating the difference in the values for the Ct for the treated and the sham-treated samples from each experiment as follows:

Formula

Statistical analysis. Data are expressed as means ± SE. N represents the number of experiments. Differences between treatment groups were determined using paired or unpaired two-tailed Student's t-test or ANOVA. Differences were considered statistically significant when P < 0.05.


   RESULTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 GRANTS
 REFERENCES
 
Depletion of ILK protein in airway smooth muscle tissues increases the expression of smooth muscle-specific genes. We evaluated the role of ILK in regulating the phenotype of intact tracheal smooth muscle tissues by introducing ILK antisense into the muscle tissues to deplete ILK protein using the reversible permeabilization procedure. Tissues were then incubated in DMEM at 37°C without serum for 1 day, after which gene and protein expression was evaluated. Sham-treated tissues were subjected to identical procedures and incubation protocols except that antisense was omitted.

Treatment of the tissues with ILK antisense resulted in significant depletion of ILK protein to 48 ± 9% (n = 6) of that of sham-treated tissues, whereas treatment with ILK sense ODNs had no significant effect on the expression of ILK (Fig. 1, A and B). ILK depletion also significantly depressed the contractile response of the tissues to ACh to 40.9 ± 7.2% (n = 6) of force in sham-treated tissues (data not shown). Myosin light chain phosphorylation was reduced from 49.2 ± 2.2% in sham-treated muscles to 42.5 ± 2.2% in ILK antisense-treated tissues (n = 4, P < 0.05). Neither ILK sense nor sham-treatment significantly affected the contractile response to ACh.


Figure 1
View larger version (27K):
[in this window]
[in a new window]

  		Fig. 1. Treatment with integrin-linked kinase (ILK) antisense depresses ILK protein expression in airway smooth muscle tissues. A: immunoblot illustrating the effects of ILK antisense treatment on ILK protein expression. ILK protein was depleted by treating smooth muscle tissues with ILK antisense (ILK-AS) for 24 h. Treatment with ILK sense (ILK-S) had no effect on the expression of ILK protein. Sham-treated muscles were subjected to identical procedures in the absence of oligonucleotides. B: mean expression levels of ILK protein in tissues treated with ILK-AS or ILK-S, normalized to protein levels in sham-treated tissues. ILK protein was significantly decreased in tissues treated with ILK antisense but was unaffected by treatment with ILK sense. Means ± SE (n = 6). *Significantly different from sham treated, P < 0.05.

 
Real-time quantitative RT-PCR was performed to evaluate the mRNA levels for SmMHC, SM22{alpha}, calponin h1, and {alpha}-actinin in extracts from smooth muscle tissues treated with ILK antisense. ILK depletion significantly increased the levels of mRNA for SmMHC to 2.41 ± 0.23 (n = 4), for SM22{alpha} to 2.08 ± 0.08 (n = 6), and for calponin to 1.47 ± 0.15 (n = 5) times that of sham-treated tissues. Depletion of ILK did not significantly affect the levels of mRNA for {alpha}-actinin (n = 3) (Fig. 2A).


Figure 2
View larger version (22K):
[in this window]
[in a new window]

  		Fig. 2. Depletion of ILK increased mRNA levels for smooth muscle myosin heavy chain (SmMHC), SM22{alpha}, and calponin and SmMHC protein in tracheal smooth muscle tissues. A: mean expression of mRNA transcripts for smooth muscle-specific genes as measured by quantitative RT-PCR. Values for each experiment were the average of measurements from duplicate or triplicate muscle tissues for each treatment, normalized to values for sham-treated muscles. N represents the no. of experiments. Values are means ± SE. Depletion of ILK protein significantly increased the mRNA levels for SmMHC (n = 4), SM22{alpha} (n = 6), and calponin (n = 5), but it did not significantly affect mRNA levels of {alpha}-actinin (n = 3). *Significantly different from 1 (sham-treated), P < 0.05. B: immunoblot of proteins from extracts of sham-treated and ILK-AS treated muscle tissues. ILK depletion significantly increased SmMHC protein expression, but it did not significantly affect SM22{alpha}, calponin, or {alpha}-actinin expression in tracheal muscle tissues. C: mean results for the effect of ILK depletion on protein expression. SmMHC is significantly increased relative to sham-treated tissues (n = 6). The expression of SM22{alpha} (n = 6) and calponin (n = 6) was not significantly altered relative to sham-treated tissues. The expression level of each protein in AS-treated tissues is normalized to the level of {alpha}-actinin in the same sample. Values are means ± SE. *Significantly different from 1 ({alpha}-actinin), P < 0.05.

 
The effect of depleting ILK protein on the expression of SmMHC, SM22{alpha}, calponin h1, and {alpha}-actinin protein was evaluated in tracheal smooth muscle tissues by immunoblot (Fig. 2, B and C). Expression levels of SmMHC, SM22{alpha}, and calponin h1 were normalized to that of {alpha}-actinin. ILK depletion significantly increased the expression of SmMHC by 2.31 ± 0.58 (n = 6) times that of sham-treated tissues, but it did not significantly affect the expression of SM22{alpha} (n = 6) or calponin (n = 6).

The depletion of ILK protein increases the amount of SRF in the nucleus of freshly dissociated smooth muscle cells (Fig. 3). Smooth muscle cells were enzymatically dissociated from sham-treated or ILK antisense-treated tracheal smooth muscle tissues and immunofluorescently stained with SRF antibody. SRF localization in the cells was analyzed by confocal microscopy. More SRF protein was observed in the nucleus of cells dissociated from tissues depleted of ILK compared with cells dissociated from sham-treated tissues (Fig. 3A). Differences in the ratio of SRF in the nucleus vs. the cytoplasm were quantitated in individual cells by comparing the ratios of average pixel intensity of cross-sectional line scans through the nucleus and the cytoplasm (Fig. 3, A–C). The ratio of nuclear to cytoplasmic SRF was significantly elevated in both sham-treated cells (1.3 ± 0.1, 47 cells from 12 muscle tissues) and cells from ILK antisense-treated tissues (2.7 ± 0.2, 43 cells from 8 muscle tissues); however, the ratio of nuclear to cytoplasmic SRF was significantly higher in ILK anstisense-treated tissues than in sham-treated tissues (Fig. 3C). We also used immunoblots to compare the amount of SRF in extracts from nuclear and cytoplasmic fractions prepared from sham-treated smooth muscle tissues and tissues treated with ILK antisense (Fig. 3, D and E). Significantly more SRF was found in the nuclear fractions obtained from ILK antisense-treated tissues compared with those from sham-treated tissues (n = 3, P < 0.05). Taken together, these results indicate that the depletion of ILK from smooth muscle tissues leads to an increase in the amount of SRF in the nucleus.


Figure 3
View larger version (26K):
[in this window]
[in a new window]

  		Fig. 3. Depletion of ILK protein in tracheal muscle tissues by ILK antisense increases the amount of SRF in the nucleus. A: tracheal muscle cells were enzymatically dissociated from tissues that had been depleted of ILK with antisense or that were sham-treated. Cells were immunostained for serum response factor (SRF) (green) and counterstained for nuclear DNA with propidium iodide (PI) (red). Yellow color indicates colocalization. White lines illustrate line scans for quantitation of pixel intensity. More SRF was localized to the nucleus of muscle cells from ILK antisense-treated tissues than in cells from sham-treated tissues. B: method for the quantitative analysis of SRF localization. The pixel intensity of SRF was quantified using a series of cross-sectional line scans through the area of the nucleus (3 lines) and the cytoplasm (4 lines). The ratio of nuclear to cytoplasmic SRF was determined for each cell by calculating the average pixel intensity of the lines across the nucleus relative to the cytoplasm. C: ratio of nuclear to cytoplasmic SRF was significantly higher in ILK-depleted tissues compared with sham-treated tissues. Values are means ± SE. *Significant difference between cells from sham-treated (n = 47) and ILK-AS-treated (n = 43) tissues, P < 0.05. The ratio of nuclear/cytoplasmic SRF was significantly greater than 1 in both groups of cells. D: nuclear and cytoplasmic extracts were prepared from sham-treated smooth muscle tissues and tissues treated with ILK antisense and were subjected to immunoblotting for SRF protein. More SRF was observed in nuclear extracts from ILK antisense-treated tissues than from sham-treated tissues. Glyceraldehyde-3-phosphate dehydrogenase was used as cytoplasmic marker. E: mean results for the effect of ILK depletion on the nuclear SRF. The amount of nuclear SRF was significantly increased in ILK-depleted tissues compared with sham-treated tissues. Values are means ± SE (n = 3). *P < 0.01.

 
ILK protein depletion increases SRF binding to the CArG box sequences of the SmMHC, SM22{alpha}, and calponin promoters in smooth muscle tissues (Fig. 4) . Chromatin immunoprecipitation was used to evaluate the effect of ILK depletion on the binding of SRF to CArG box sequences within the promoter regions of SmMHC, SM22{alpha}, and calponin genes. DNA fragments bound to SRF were immunoprecipitated using SRF antibody from extracts of smooth muscle tissues treated with ILK antisense and from sham-treated tissues. The amounts of SmMHC, SM22{alpha}, and calponin promoters in the immunoprecipitates were quantitated by real-time PCR. Binding of SRF to the {alpha}-actinin promoter was also evaluated as a negative control. The amounts of promoter DNA bound to SRF in chromatin extracted from ILK antisense-treated tissues was significantly higher than that in sham-treated tissues for SmMHC (2.24 ± 0.42, n = 4), SM22{alpha} (2.10 ± 0.40, n = 4), and calponin h1 (1.54 ± 0.26, n = 4) (Fig. 4). There was no detectible binding of SRF to the {alpha}-actinin promoter.


Figure 4
View larger version (9K):
[in this window]
[in a new window]

  		Fig. 4. Depletion of ILK protein expression increased the binding of SRF to the promoters of SmMHC, SM22{alpha}, and calponin in tracheal smooth muscle tissues. SRF was immunoprecipitated from chromatin extracts from ILK-depleted smooth muscle tissues. SRF immunoprecipitates were subjected to real-time PCR to amplify SmMHC, SM22{alpha}, and calponin promoter DNA. {alpha}-Actinin promoter DNA was used as a negative control for SRF binding. Depletion of ILK protein significantly increased the amount of SRF bound to the SmMHC promoter relative to sham-treated tissues (2.24 ± 0.42). ILK depletion also significantly increased the amount of SRF bound to the SM22{alpha} (2.10 ± 0.40) and calponin (1.54 ± 0.26) promoters compared with sham-treated tissues. Binding of SRF to the {alpha}-actinin promoter was negligible in extracts from both ILK-AS-treated and sham-treated tissues. Results represent means from 4 separate experiments. Values are means ± SE (n = 4). *Significantly different from sham-treated tissues (P < 0.05).

 
Overexpression of ILK protein expression regulates smooth muscle-specific gene and protein expression in airway smooth muscle tissues. ILK depletion may prevent the assembly of macromolecular protein complexes at adhesion sites (38, 40) and thus might affect gene and protein expression by disrupting signaling pathways mediated by other protein constituents of these adhesion complexes. We therefore evaluated whether an increase in ILK expression also modulates the expression of smooth muscle-specific proteins and genes, since an increase in ILK expression would not disrupt the assembly of macromolecular protein complexes at adhesion sites.

ILK was overexpressed by introducing plasmids encoding recombinant human ILK-FLAG in intact tissues strips by reversible permeabilization. The overexpression of ILK in the tissues was confirmed 2 days after the introduction of ILK plasmids by immunoblotting with an ILK antibody (Fig. 5, A and B) and further confirmed by immunoprecipitation using a FLAG antibody (Fig. 5C). Tissues treated with plasmids encoding recombinant ILK-FLAG wild type showed a 44% increase in total ILK protein expression relative to sham-treated tissues (1.44 ± 0.25, n = 14). The overexpression of ILK did not significantly affect contractile force in response to ACh (102 ± 1.5% of force in sham-treated tissues, n = 5).


Figure 5
View larger version (22K):
[in this window]
[in a new window]

  		Fig. 5. Treatment of airway smooth muscle tissues with ILK plasmids caused an increase in ILK protein expression. A: immunoblot indicating the effects of transfection with plasmids encoding WT-ILK on ILK protein expression. Treatment of smooth muscle tissues with ILK-WT plasmids followed by 2 days incubation caused upregulation of ILK protein expression (ILK Overexp). B: mean expression level of ILK protein in tissues treated with ILK plasmids relative to sham-treated tissues. ILK protein was significantly increased in tissues transfected with ILK plasmids (n = 14). Values are means ± SE. *Significantly different from 1 (Sham treated), P < 0.05. C: expression of recombinant FLAG-ILK protein was confirmed by immunoprecipitation of recombinant ILK from muscle extracts using anti-Flag antibody (Ab) followed by immunoblot using ILK Ab.

 
Real-time quantitative RT-PCR was performed to evaluate the mRNA levels for SmMHC, SM22{alpha}, calponin h1, and {alpha}-actinin in extracts from smooth muscle tissues treated with ILK wild-type plasmids (Fig. 6A). ILK overexpression resulted in a significant decrease in the level of mRNA for SmMHC to 0.44 ± 0.052 (n = 5), for SM22{alpha} to 0.62 ± 0.11 (n = 8), and for calponin to 0.72 ± 0.04 (n = 4) relative to sham-treated tissues. The level of mRNA for {alpha}-actinin was not significantly different from that in sham-treated muscles (n = 4).


Figure 6
View larger version (13K):
[in this window]
[in a new window]

  		Fig. 6. Overexpression of ILK decreases gene expression and SRF binding to the promoters of SmMHC, SM22{alpha}, and calponin. A: mean expression of mRNA transcripts for smooth muscle-specific genes as measured by quantitative RT-PCR. mRNA expression levels are expressed relative to values for sham-treated tissues. "N" represents the no. of separate experiments for each treatment. Values for each experiment were the average of measurements from duplicate or triplicate muscle tissues for each treatment. Values are means ± SE. Overexpression of ILK significantly decreased mRNA levels for SmMHC (n = 5), SM22{alpha} (n = 8), and calponin (n = 4), but ILK overexpression did not significantly affect mRNA levels for {alpha}-actinin (n = 4). B: SRF was immunoprecipitated from chromatin extracts from ILK-depleted smooth muscle tissues. SRF immunoprecipitates were subjected to real-time PCR to amplify SmMHC, SM22{alpha}, and calponin promoter DNA. {alpha}-Actinin promoter DNA was used as a negative control for SRF binding. The overexpression of ILK protein significantly decreased the amount of SRF binding to the promoters of SmMHC (0.58 ± 0.06), SM22{alpha} (0.65 ± 0.07), and calponin (0.79 ± 0.05) relative to sham-treated tissues.

 
We also used chromatin immunoprecipitation to evaluate the effect of ILK overexpression on the binding of SRF to CArG box sequences within the promoter regions of SmMHC, SM22{alpha}, and calponin genes (Fig. 6B). The amounts of SmMHC (0.58 ± 0.06, n = 4), {alpha}-SM22{alpha} (0.65 ± 0.07, n = 4), and calponin (0.79 ± 0.05, n = 4) promoters in SRF immunoprecipitates were significantly decreased in tissues overexpressing ILK relative to sham-treated tissues (P < 0.05).

The effect of overexpressing ILK protein on the expression of SmMHC, SM22{alpha}, calponin h1, and {alpha}-actinin protein was evaluated in tracheal smooth muscle tissues by immunoblot (Fig. 7). The overexpression of ILK protein resulted in a significant decrease in the expression of SmMHC expression to 0.67 ± 0.07 (n = 9) of the level in sham-treated muscles, whereas the expression of SM22{alpha} (n = 4) and calponin (n = 4) was not significantly affected (Fig. 7B).


Figure 7
View larger version (32K):
[in this window]
[in a new window]

  		Fig. 7. Expression of smooth muscle SmMHC was decreased in tissues overexpressing ILK. A: immunoblots from extracts of tissues treated with ILK plasmids or sham treated. Expression of SmMHC is decreased in tissues overexpressing ILK, whereas there is little effect on the expression of SM22{alpha}, calponin, and {alpha}-actinin. B: mean results for the effect of ILK overexpression on protein expression. SmMHC expression is significantly decreased relative to sham-treated tissues (n = 9). The expressions of SM22{alpha} (n = 4) and calponin (n = 4) were not significantly affected by ILK overexpression. Amount of each protein is normalized to that of {alpha}-actinin in the same sample. Values are means ± SE. *Significantly different from 1 (sham treated), P < 0.05.

 
ILK may regulate smooth muscle-specific gene expression by regulating Akt/PKB activity. ILK has been implicated in the activation of PKB/Akt (8, 29, 33), which can regulate the expression of smooth muscle differentiation marker genes and proteins (6, 13, 17, 20). We evaluated the effects of ILK depletion and ILK overexpression on the activation of PKB/Akt in tracheal smooth muscle tissues by measuring the phosphorylation of Akt at Ser473. Akt phosphorylation at Ser473 was significantly depressed in ILK-depleted tissues to 58.9 ± 0.8% of sham-treated tissues (n = 3), and Akt phosphorylation at Ser473 was significantly increased in ILK-overexpressing tissues to 1.76 ± 0.33 of sham-treated muscles (n = 4) (Fig. 8, A and B).


Figure 8
View larger version (27K):
[in this window]
[in a new window]

  		Fig. 8. ILK depletion and ILK overexpression regulates protein kinase B (Akt) phosphorylation in smooth muscle tissues. A: ILK antisense treatment for 24 h caused an inhibition of Akt phosphorylation at Ser473 in smooth muscle tissues, indicating Akt inactivation. In contrast, ILK overexpression increased Akt phosphorylation at Ser473, indicating Akt activation. B: mean values for effect of ILK depletion (n = 3) or overexpression (n = 4) on Akt phosphorylation at Ser473 (means ± SE). *Significantly different from sham-treated tissues, P < 0.05.

 
Inhibition of Akt increases smooth muscle-specific gene expression and SRF binding to CArG box sequences of the SmMHC and SM22{alpha} genes. We then evaluated the effect of inhibiting PKB/Akt activity on the expression of SmMHC, SM22{alpha}, and calponin h1 in tracheal smooth muscle tissues. Smooth muscle tissues were treated for 6–16 h with 50 µM Akt inhibitor VIII (21) (Fig. 9, A and B). Akt phosphorylation at Ser473 was depressed after this treatment, confirming the effectiveness of the Akt inhibitor at inactivating Akt. Treatment of muscle tissues for 6–16 h with the Akt inhibitor resulted in a 1.9 ± 0.30-fold increase in SmMHC expression and a 1.28 ± 0.05-fold increase in SM22{alpha} but did not significantly affect expression of calponin. The increase in SmMHC expression was evident 6 h after the inhibitor was administered and persisted for at least 20 h.


Figure 9
View larger version (21K):
[in this window]
[in a new window]

  		Fig. 9. Akt inhibitor treatment increased expression of smooth muscle-specific proteins and increased SRF binding to the promoters of smooth muscle-specific genes. A: treatment of muscle tissues with 50 µM Akt inhibitor VIII significantly inhibits Akt phosphorylation at Ser473. Akt treatment substantially increased SmMHC protein expression, but had less effect on the expression of SM22{alpha} and calponin h1. B: mean effect of Akt inhibition on SmMHC (n = 8), SM22{alpha} (n = 4), and calponin (n = 4) expression. Values are means ± SE. *Values are significantly different from untreated tissues, P < 0.05. C: SRF was immunoprecipitated from chromatin extracts from Akt inhibitor-treated and untreated smooth muscle tissues. SRF immunoprecipitates were subjected to real-time PCR to amplify SmMHC, SM22{alpha}, and calponin promoter DNA. {alpha}-Actinin promoter DNA was used as a negative control for SRF binding. Akt inhibitor treatment significantly increased the amount of SRF binding to the promoters of SmMHC and SM22{alpha} relative to untreated tissues.

 
Chromatin immunoprecipitation was used to evaluate the effect of Akt inhibition on the binding of SRF to CArG box sequences within the promoter regions of SmMHC, SM22{alpha}, and calponin genes. The amounts of promoter DNA bound to SRF in chromatin extracted from tissues treated with the Akt inhibitor were significantly higher than those in untreated tissues for SmMHC (1.6 ± 0.25, n = 3) and SM22{alpha} (1.4 ± 0.15, n = 3). The increase in SRF binding to calponin was not significantly different from that of untreated muscles (1.2 ± 0.12, n = 3) (Fig. 9C). There was no detectible binding of SRF to the {alpha}-actinin promoter.


   DISCUSSION
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
GRANTS
 REFERENCES
 
The results of our study demonstrate that the adhesion complex protein ILK regulates the expression of smooth muscle-specific genes in intact differentiated tracheal smooth muscle tissues. This is the first demonstration that ILK mediates signaling pathways that regulate the phenotype of smooth muscle. We found that ILK modulates its effects on airway smooth muscle gene transcription by activating the phosphoinositide-dependent kinase Akt/PKB, a downstream effector and substrate of ILK (1, 8, 29, 33), and that the activation of Akt suppresses gene transcription by inhibiting activity of the transcriptional regulator SRF. ILK binds to the cytoplasmic tails of β-integrin proteins where it regulates the organization of macromolecular signaling complexes at extracellular matrix/cytoskeletal junctions in tracheal smooth muscle tissues (38). Thus our results suggest that ILK may regulate nuclear signaling pathways that control the differentiation and phenotype of airway smooth muscle in response to signals from integrin receptors. This pathway may represent a physiologically important mechanism for regulating the phenotype of airway smooth muscle in response to physiological or pathophysiological conditions that alter the extracellular matrix.

Extensive previous studies have shown that the binding of SRF to CArG box elements within genes encoding SmMHC, calponin h1, and SM22{alpha} is essential for their transcription (24, 25). Our analysis by chromatin immunoprecipitation detected a pronounced increase in the amount of SRF bound to the promoter regions of genes encoding SmMHC, calponin h1, and SM22{alpha} in nuclear extracts from ILK-depleted tissues and a reduction in SRF bound to the promoter regions of these genes in tissues overexpressing ILK. We also observed a marked increase in nuclear SRF in cells dissociated from tracheal tissues depleted of ILK and more SRF in the nuclear fractions of extracts from the ILK-depleted tissues. Together, these data suggest that ILK regulates the activation of SRF to control the transcription of genes of smooth muscle-specific contractile proteins.

Our results suggest that ILK regulates SRF activity in tracheal smooth muscle tissues through its effects on the activity of the protein kinase Akt/PKB, a substrate of ILK (1, 8, 29, 33). Akt has been implicated in the control of airway and vascular smooth muscle phenotypic modulation by both transcriptional and posttranscriptional mechanisms (2, 6, 13, 20). We observed that Akt activation, as indicated by its phosphorylation on Ser473, was significantly lower in ILK-depleted tracheal smooth muscle tissues and significantly higher in tissues overexpressing ILK. We also found that the pharmacological inhibition of Akt activity increased the binding of SRF to SmMHC promoter and increased the expression of SmMHC in tissues. Previous studies have also implicated Akt in the regulation of SRF activity (11). Kaplan-Albuquerque et al. (20) reported that, in cultured rat aortic vascular smooth muscle cells, the platelet-derived growth factor-mediated activation of Akt suppressed the expression of smooth muscle {alpha}-actin and SM22{alpha} proteins by decreasing SRF localization to the nucleus. Our results suggest that an analogous mechanism may account for the effects of ILK depletion and overexpression on SRF-dependent gene expression in tracheal muscle tissues.

We observed that the depletion of ILK protein in airway muscle tissues increased the levels of mRNA transcripts for the smooth muscle differentiation marker genes SmMHC, calponin h1, and SM22{alpha}, and it also increased the binding of SRF to the promoter regions of their genes. In contrast, ILK overexpression decreased the levels of mRNA transcripts for these proteins and decreased binding of SRF to their promoters. In each of our experiments, changes in the expression of SmMHC were greater than the changes in calponin h1 or SM22{alpha}. Our observations are consistent with observations of the effects of serum deprivation on cultured canine tracheal smooth muscle cells, in which serum deprivation was found to increase the expression of SmMHC proportionally more than that of other smooth muscle phenotypic marker proteins (12). At the protein level, we were able to detect parallel changes in the levels of SmMHC but not of calponin h1 or SM22{alpha}. Our inability to detect changes in expression of Sm22{alpha} and calponin proteins that correspond to the changes in their mRNA levels may simply reflect the more quantitative nature of our mRNA analysis compared with our Western blot analysis of protein expression. Differences in the sensitivity of the expression of smooth muscle phenotypic marker proteins to stimuli that regulate differentiation might result from a number of factors: differences in the rate of protein turnover or degradation, the amount of protein synthesis relative to basal protein expression, the activity of transcriptional cofactors that interact with SRF to regulate promoter activity (23), or posttranscriptional mechanisms that regulate the stability of mRNA or protein expression (2, 13). However, our results demonstrate that the activity of all of these SRF-dependent genes is regulated by ILK.

Akt can regulate protein expression in airway smooth muscle cells by modulating ribosomal translation through its downstream targets mammalian target of rapamycin (mTOR) and p70 ribosomal S6 kinase (p70S6K) (2, 13). The stimulation of serum-deprived cultured canine airway smooth muscle cells with insulin activates a signaling pathway mediated by phosphatidylinositol 3-kinase, Akt, and ribosomal protein regulator p70S6K that leads to smooth muscle cell hypertrophy and the accumulation of SM22{alpha} and SmMHC without affecting levels of mRNA for these proteins (13). Our studies do not exclude the possibility that ILK regulates protein translation in addition to gene transcription. However, we observed that ILK depletion was associated with a decrease in Akt phosphorylation and an increase in expression of SRF-dependent gene transcripts and that the inhibition of Akt activation also increased SmMHC mRNA. These observations are inconsistent with ILK/Akt-mediated stimulation of ribosomal translation of SmMHC through the mTOR p70S6K pathway. The differences between the results of our study and those of previous investigators may reflect differences in effects of Akt activity in cultured tracheal smooth muscle cells and intact tracheal tissues, or they may have resulted from the presence of insulin and other growth factors in the serum of the tracheal cells in culture that were not present in the incubation medium of the tracheal muscle tissues in our study (13).

We previously demonstrated that ILK provides a scaffold for the formation of a macromolecular protein complex that associates with the cytoplasmic tail of β-integrins in airway smooth muscle (38). Contractile stimulation causes the recruitment of structural and signaling proteins to this complex, and this complex then regulates changes in cytoskeletal structure and organization that occur during contractile activation (35, 40). When we inhibited the formation of this ILK-associated macromolecular complex in tracheal muscle tissues, actin polymerization and the development of active tension were inhibited, and myosin light chain phosphorylation was somewhat reduced. Consistent with our previous results, the depletion of ILK from tracheal muscle tissues by antisense also depressed contractile force and somewhat reduced myosin light chain phosphorylation. It is likely that this effect dominated any possible effects on contractile force that might have resulted from the enhanced expression of SmMHC. The overexpression of ILK, which reduced the expression of SmMHC, did not have a detectable effect on force; however, given the variability in force development between different strips of muscle, subtle effects on tension would be difficult to detect experimentally.

In conclusion, our results demonstrate that ILK is a critical mediator of a pathway that regulates gene transcription and smooth muscle phenotype expression in intact airway smooth muscle tissues. Phenotypic changes in airway smooth muscle are associated with pathophysiological conditions such as asthma that cause inflammation of the smooth muscle tissues and alter the extracellular matrix of the smooth muscle cells. ILK may be an important intermediary in a pathway by which signals from transmembrane integrin receptors regulate the differentiation state of airway smooth muscle cells in intact tissues in vivo in response to physiological and pathophysiological conditions that lead to alterations in the extracellular matrix.


   GRANTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
REFERENCES
 
These studies were supported by National Heart, Lung, and Blood Institute Grants RO1 HL-29289 and HL-074099 and by an American Heart Association Postdoctoral Fellowship to Y. Wu.


   ACKNOWLEDGMENTS
 
We thank Min Zhang for assistance with the chromatin immunoprecipitation assay.


   FOOTNOTES
 

Address for reprint requests and other correspondence: S. J. Gunst, Dept. of Cellular & Integrative Physiology, Indiana Univ. School of Medicine, 635 Barnhill Dr., Indianapolis, IN 46202-5120 (e-mail: sgunst{at}iupui.edu)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   REFERENCES
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 

  1. Attwell S, Mills J, Troussard A, Wu C, Dedhar S. Integration of cell attachment, cytoskeletal localization, and signaling by integrin-linked kinase (ILK), CH-ILKBP, and the tumor suppressor PTEN. Mol Biol Cell 14: 4813–4825, 2003.[Abstract/Free Full Text]
  2. Bentley JK, Hershenson MB. Airway smooth muscle growth in asthma: proliferation, hypertrophy, and migration. Proc Am Thorac Soc 5: 89–96, 2008.[Abstract/Free Full Text]
  3. Brakebusch C, Fassler R. The integrin-actin connection, an eternal love affair. EMBO J 22: 2324–2333, 2003.[CrossRef][Web of Science][Medline]
  4. Burkin DJ, Kaufman SJ. The alpha7beta1 integrin in muscle development and disease. Cell Tissue Res 296: 183–190, 1999.[CrossRef][Web of Science][Medline]
  5. Chamley-Campbell J, Campbell GR, Ross R. The smooth muscle cell in culture. Physiol Rev 59: 1–61, 1979.[Free Full Text]
  6. Chen CN, Li YS, Yeh YT, Lee PL, Usami S, Chien S, Chiu JJ. Synergistic roles of platelet-derived growth factor-BB and interleukin-1beta in phenotypic modulation of human aortic smooth muscle cells. Proc Natl Acad Sci USA 103: 2665–2670, 2006.[Abstract/Free Full Text]
  7. Dedhar S, Williams B, Hannigan G. Integrin-linked kinase (ILK): a regulator of integrin and growth-factor signalling. Trends Cell Biol 9: 319–323, 1999.[CrossRef][Web of Science][Medline]
  8. Delcommenne M, Tan C, Gray V, Rue L, Woodgett J, Dedhar S. Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proc Natl Acad Sci USA 95: 11211–11216, 1998.[Abstract/Free Full Text]
  9. Flintoff-Dye NL, Welser J, Rooney J, Scowen P, Tamowski S, Hatton W, Burkin DJ. Role for the alpha7beta1 integrin in vascular development and integrity. Dev Dyn 234: 11–21, 2005.[CrossRef][Web of Science][Medline]
  10. Fukuda T, Chen K, Shi XH, Wu CY. PINCH-1 is an obligate partner of integrin-linked kinase (ILK) functioning in cell shape modulation, motility, and survival. J Biol Chem 278: 51324–51333, 2003.[Abstract/Free Full Text]
  11. Fukuda T, Guo L, Shi XH, Wu CY. CH-ILKBP regulates cell survival by facilitating the membrane translocation of protein kinase B/Akt. J Cell Biol 160: 1001–1008, 2003.[Abstract/Free Full Text]
  12. Halayko AJ, Camoretti-Mercado B, Forsythe SM, Vieira JE, Mitchell RW, Wylam ME, Hershenson MB, Solway J. Divergent differentiation paths in airway smooth muscle culture: induction of functionally contractile myocytes. Am J Physiol Lung Cell Mol Physiol 276: L197–L206, 1999.[Abstract/Free Full Text]
  13. Halayko AJ, Kartha S, Stelmack GL, McConville J, Tam J, Camoretti-Mercado B, Forsythe SM, Hershenson MB, Solway J. Phophatidylinositol-3 kinase/mammalian target of rapamycin/p70(S6K) regulates contractile protein accumulation in airway myocyte differentiation. Am J Respir Cell Mol Biol 31: 266–275, 2004.[Abstract/Free Full Text]
  14. Halayko AJ, Salari H, MAX, Stephens NL. Markers of airway smooth muscle cell phenotype. Am J Physiol Lung Cell Mol Physiol 270: L1040–L1051, 1996.[Abstract/Free Full Text]
  15. Halayko AJ, Solway J. Molecular mechanisms of phenotypic plasticity in smooth muscle cells. J Appl Physiol 90: 358–368, 2001.[Abstract/Free Full Text]
  16. Hannigan GE, Leung-Hagesteijn C, Fitz-Gibbon L, Coppolino MG, Radeva G, Filmus J, Bell JC, Dedhar S. Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-integrin-linked protein kinase. Nature 379: 91–96, 1996.[CrossRef][Web of Science][Medline]
  17. Hayashi K, Takahashi M, Kimura K, Nishida W, Saga H, Sobue K. Changes in the balance of phosphoinositide 3-kinase/protein kinase B (Akt) and the mitogen-activated protein kinases (ERK/p38MAPK) determine a phenotype of visceral and vascular smooth muscle cells. J Cell Biol 145: 727–740, 1999.[Abstract/Free Full Text]
  18. Hirst SJ. Airway smooth muscle cell culture: application to studies of airway wall remodelling and phenotype plasticity in asthma. Eur Respir J 9: 808–820, 1996.[Abstract]
  19. Hirst SJ, Twort CH, Lee TH. Differential effects of extracellular matrix proteins on human airway smooth muscle cell proliferation and phenotype. Am J Respir Cell Mol Biol 23: 335–344, 2000.[Abstract/Free Full Text]
  20. Kaplan-Albuquerque N, Garat C, Desseva C, Jones PL, Nemenoff RA. Platelet-derived growth factor-BB-mediated activation of akt suppresses smooth muscle-specific gene expression through inhibition of mitogen-activated protein kinase and redistribution of serum response factor. J Biol Chem 278: 39830–39838, 2003.[Abstract/Free Full Text]
  21. Logie L, Ruiz-Alcaraz AJ, Keane M, Woods YL, Bain J, Marquez R, Alessi DR, Sutherland C. Characterization of a protein kinase B inhibitor in vitro and in insulin-treated liver cells. Diabetes 56: 2218–2227, 2007.[CrossRef][Web of Science][Medline]
  22. McDonald KA, Lakonishok M, Horwitz AF. Alpha v and alpha 3 integrin subunits are associated with myofibrils during myofibrillogenesis. J Cell Sci 108: 2573–2581, 1995.[Abstract]
  23. McDonald OG, Owens GK. Programming smooth muscle plasticity with chromatin dynamics. Circ Res 100: 1428–1441, 2007.[Abstract/Free Full Text]
  24. McDonald OG, Wamhoff BR, Hoofnagle MH, Owens GK. Control of SRF binding to CArG box chromatin regulates smooth muscle gene expression in vivo. J Clin Invest 116: 36–48, 2006.[CrossRef][Web of Science][Medline]
  25. Miano JM. Serum response factor: toggling between disparate programs of gene expression. J Mol Cell Cardiol 35: 577–593, 2003.[CrossRef][Web of Science][Medline]
  26. Nikolopoulos SN, Turner CE. Integrin-linked kinase (ILK) binding to paxillin LD1 motif regulates ILK localization to focal adhesions. J Biol Chem 276: 23499–23505, 2001.[Abstract/Free Full Text]
  27. Opazo SA, Zhang W, Wu Y, Turner CE, Tang DD, Gunst SJ. Tension development during contractile stimulation of smooth muscle requires recruitment of paxillin and vinculin to the membrane. Am J Physiol Cell Physiol 286: C433–C447, 2004.[Abstract/Free Full Text]
  28. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 84: 767–801, 2004.[Abstract/Free Full Text]
  29. Persad S, Attwell S, Gray V, Delcommenne M, Troussard A, Sanghera J, Dedhar S. Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc Natl Acad Sci USA 97: 3207–3212, 2000.[Abstract/Free Full Text]
  30. Sastry SK, Lakonishok M, Thomas DA, Muschler J, Horwitz AF. Integrin alpha subunit ratios, cytoplasmic domains, and growth factor synergy regulate muscle proliferation and differentiation. J Cell Biol 133: 169–184, 1996.[Abstract/Free Full Text]
  31. Tang DD, Gunst SJ. Depletion of focal adhesion kinase by antisense depresses contractile activation of smooth muscle. Am J Physiol Cell Physiol 280: C874–C883, 2001.[Abstract/Free Full Text]
  32. Tran T, Halayko AJ. Extracellular matrix and airway smooth muscle interactions: a target for modulating airway wall remodelling and hyperresponsiveness? Can J Physiol Pharmacol 85: 666–671, 2007.[CrossRef][Medline]
  33. Troussard AA, Mawji NM, Ong C, Mui A, Arnaud R, Dedhar S. Conditional knock-out of integrin-linked kinase demonstrates an essential role in protein kinase B/Akt activation. J Biol Chem 278: 22374–22378, 2003.[Abstract/Free Full Text]
  34. Woodruff PG. Gene expression in asthmatic airway smooth muscle. Proc Am Thorac Soc 5: 113–118, 2008.[Abstract/Free Full Text]
  35. Wu C, Dedhar S. Integrin-linked kinase (ILK) and its interactors: a new paradigm for the coupling of extracellular matrix to actin cytoskeleton and signaling complexes. J Cell Biol 155: 505–510, 2001.[Abstract/Free Full Text]
  36. Zargham R, Thibault G. Alpha 8 integrin expression is required for maintenance of the smooth muscle cell differentiated phenotype. Cardiovasc Res 71: 170–178, 2006.[Abstract/Free Full Text]
  37. Zhang W, Wu Y, Du L, Tang DD, Gunst SJ. Activation of the Arp2/3 complex by N-WASp is required for actin polymerization and contraction in smooth muscle. Am J Physiol Cell Physiol 288: C1145–C1160, 2005.[Abstract/Free Full Text]
  38. Zhang W, Wu Y, Wu C, Gunst SJ. Integrin-linked kinase (ILK) regulates N-WASp-mediated actin polymerization and tension development in tracheal smooth muscle. J Biol Chem 282: 34568–34580, 2007.[Abstract/Free Full Text]
  39. Zhang WW, Gunst SJ. Dynamic association between alpha-actinin and beta-integrin regulates contraction of canine tracheal smooth muscle. J Physiol Lond 572: 659–676, 2006.[Abstract/Free Full Text]
  40. Zhang YJ, Chen K, Tu YZ, Velyvis A, Yang YW, Qin J, Wu CY. Assembly of the PINCH-ILK-CH-ILKBP complex precedes and is essential for localization of each component to cell-matrix adhesion sites. J Cell Sci 115: 4777–4786, 2002.[CrossRef][Web of Science][Medline]
  41. Zhang YJ, Guo LD, Chen K, Wu CY. A critical role of the PINCH-integrin-linked kinase interaction in the regulation of cell shape change and migration. J Biol Chem 277: 318–326, 2002.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
W.-C. Zhang, Y.-J. Peng, G.-S. Zhang, W.-Q. He, Y.-N. Qiao, Y.-Y. Dong, Y.-Q. Gao, C. Chen, C.-H. Zhang, W. Li, et al.
Myosin Light Chain Kinase Is Necessary for Tonic Airway Smooth Muscle Contraction
J. Biol. Chem., February 19, 2010; 285(8): 5522 - 5531.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
295/6/L988    most recent
90202.2008v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wu, Y.
Right arrow Articles by Gunst, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wu, Y.
Right arrow Articles by Gunst, S. J.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2008 by the American Physiological Society.